▲ Peaking
Business
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
2 trends tracked about this subject — the full history, oldest to newest below.
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Pfizer secures up to $1.5 billion from Blackstone Life Sciences to advance a once-monthly GLP-1 obesity treatment acquired from Metsera.